Company Profile
ImmunityBio Stock Price, News & Analysis
Company overview
Business overview
ImmunityBio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, ImmunityBio is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
ImmunityBio follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, ImmunityBio sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
IBRX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
ImmunityBio’s catalysts are Anktiva launch execution, the bladder-cancer franchise, and any additional label or commercial step. The stock is still driven by whether the launch can keep scaling.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.